

CITATION REPORT

List of articles citing

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use

DOI: 10.1016/j.schres.2007.04.025
Schizophrenia Research, 2007, 94, 29-36.

Source: <https://exaly.com/paper-pdf/42377307/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
206	Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. 2008 , 118, 209-13		78
205	Cannabis and psychiatric disorders: it is not only addiction. 2008 , 13, 264-75		146
204	Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. 2008 , 58, 415-52		171
203	Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. 2008 , 8, 1037-48		89
202	Effect of social isolation on CB1 and D2 receptor and fatty acid amide hydrolase expression in rats. 2008 , 152, 265-72		53
201	Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. 2008 , 33, 2505-16		195
200	Current world literature. 2008 , 21, 211-27		
199	Phytocannabinoids and endocannabinoids. 2009 , 2, 51-75		33
198	Cannabis and schizophrenia spectrum disorders: a review of clinical studies. 2009 , 31, 62-70		6
197	Behavioral Neurobiology of the Endocannabinoid System. 2009 ,		3
196	The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. 2009 , 85, 57-72		66
195	The critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and deficiencies. 2009 , 9, 1407-15		31
194	Neurobiology and systems physiology of the endocannabinoid system. 2009 , 42 Suppl 1, S79-86		17
193	Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. 2009 , 194, 371-2		140
192	Sex-dependent alterations in response to maternal deprivation in rats. 2009 , 34 Suppl 1, S217-26		74
191	Clinical bioinformatics for complex disorders: a schizophrenia case study. 2009 , 10 Suppl 12, S6		9
190	Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. 2009 , 1253, 81-91		80

189	Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. 2009 , 19, 623-32	111
188	Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia. 2009 , 116, 923-39	37
187	The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. 2009 , 259, 371-82	71
186	An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. 2009 , 205, 63-72	33
185	The endocannabinoid system as a target for modelling psychosis. 2009 , 206, 551-61	37
184	Role of cannabis and endocannabinoids in the genesis of schizophrenia. 2009 , 206, 531-49	106
183	Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. 2009 , 23, 629-38	47
182	The endocannabinoid system as a target for the treatment of cannabis dependence. 2009 , 56 Suppl 1, 235-43	74
181	Structural Brain Alterations in Cannabis Users: Association with Cognitive Deficits and Psychiatric Symptoms. 2009 , 215-225	0
180	Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. 2009 , 12, 599-614	71
179	Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. 2010 , 21, 690-709	43
178	Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. 2010 , 208, 353-63	34
177	The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. 2010 , 1343, 153-67	43
176	Early maternal deprivation induces changes on the expression of 2-AG biosynthesis and degradation enzymes in neonatal rat hippocampus. 2010 , 1349, 162-73	40
175	Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. 2010 , 160, 511-22	155
174	Endocannabinoids and Schizophrenia. 2010 , 3, 3101-3126	21
173	Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. 2010 , 3, 2799-2820	10
172	Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. 2010 , 13, 373-86	75

171	Endocannabinoids and pregnancy. 2010 , 411, 921-30	53
170	Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. 2010 , 16, e18-42	113
169	The endocannabinoid system and psychiatric disorders. 2010 , 224, 3-14	105
168	Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. 2010 , 20, 25-36	42
167	Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. 2010 , 20, 855-65	66
166	Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. 2011 , 14, 17-28	40
165	Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective. 2011 , 1811, 706-23	118
164	Discovery and development of integrative biological markers for schizophrenia. 2011 , 95, 686-702	25
163	Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. 2011 , 188, 208-16	45
162	Cannabinoids and the cerebellum: a potential role in the development of psychosis. 144-159	1
161	Alterations of primary fatty acid amides in serum of patients with severe mental illness. 2011 , 3, 308-14	11
160	Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. 2011 , 132, 215-41	119
159	The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. 2011 , 14, 631-43	54
158	Prevalence and intensity of basic symptoms among cannabis users: an observational study. 2011 , 37, 111-6	8
157	Functional diversity on synaptic plasticity mediated by endocannabinoids. 2012 , 367, 3242-53	29
156	Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. 2012 , 42, 391-400	134
155	The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. 2012 , 26, 164-76	77
154	Biochemical markers of impending psychosis. 2012 , 18, 505-9	3

153	Neurophysiological effects of cannabinoids: implications for psychosis research. 2012 , 18, 4938-49		17
152	Anandamide dysfunction in prodromal and established psychosis. 2012 , 18, 5188-93		25
151	Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. 2012 , 18, 5141-55		17
150	Neurocognitive functioning and cannabis use in schizophrenia. 2012 , 18, 4999-5007		7
149	Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. 2012 , 18, 5070-80		47
148	Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions. 2012 , 18, 5015-23		35
147	Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?. 2012 , 262, 375-91		34
146	CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. 2012 , 26, 92-103		128
145	Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens. 2012 , 63, 565-74		23
144	Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. 2012 , 204, 207-29		124
143	Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. 2012 , 38, 68-77		19
142	New insights on endocannabinoid transmission in psychomotor disorders. 2012 , 38, 51-8		17
141	Alterations of theory of mind network activation in chronic cannabis users. <i>Schizophrenia Research</i> , 2012 , 139, 19-26	3.6	20
140	The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. 2012 , 34 Suppl 2, S163-77		18
139	Delayed preattentive functioning in early psychosis patients with cannabis use. 2012 , 222, 507-18		19
138	Endocannabinoid system: potential novel targets for treatment of schizophrenia. 2013 , 53, 10-7		31
137	Medical use of cannabis. Cannabidiol: a new light for schizophrenia?. 2013 , 5, 46-51		29
136	Confounders of excessive brain volume loss in schizophrenia. 2013 , 37, 2418-23		55

135	Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor- α gene (PPARA) and schizophrenia. 2013 , 23, 749-59	20
134	Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. 2013 , 79, 304-12	84
133	Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. 2013 , 202, 381-2	65
132	Peripheral endocannabinoid system dysregulation in first-episode psychosis. 2013 , 38, 2568-77	61
131	Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. 2014 , 8, 361	86
130	Neurobiology of Comorbid Substance Use Disorders in Mental Illness: A Closer Look at the Underlying Commonalities between Cannabis and Schizophrenia. 2014 , 1, 261-271	2
129	Sleep deprivation in humans: Effects on melatonin in cerebrospinal fluid and serum. 2014 , 12, 69-72	7
128	The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. 2014 , 5, 73	46
127	Substance use in clinical high risk for psychosis: a review of the literature. 2014 , 8, 104-12	58
126	Immune system: a possible nexus between cannabinoids and psychosis. 2014 , 40, 269-82	41
125	Cannabidiol as a potential treatment for psychosis. 2014 , 24, 51-64	62
124	Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or Δ^9 -tetrahydrocannabinol (THC). 2014 , 52, 53-69	45
123	Genes and the Motivation to Use Substances. 2014 ,	1
122	Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. 2014 , 387, 691-5	12
121	Cannabinoid-Based Drugs: Potential Applications in Addiction and Other Mental Disorders. 2015 , 13, 307-316	6
120	Cannabinoid Receptor 1 (CNR1) Gene Polymorphisms in Schizophrenia Patients: Rs6454674 Polymorphism is Associated with Disease Severity. 2015 , 25, 341-347	3
119	Cannabinoids and Endocannabinoids. 2015 , 1-31	1
118	MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. 2015 , 26, 748-65	27

117	Leptin levels are negatively correlated with 2-arachidonoylglycerol in the cerebrospinal fluid of patients with osteoarthritis. 2015 , 10, e0123132	12
116	Cannabinoids and drug addiction. 2015 , 289-313	1
115	Cannabinoids and schizophrenia. 2015 , 193-204	1
114	Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. 2015 , 12, 816-24	34
113	Endocannabinoid signalling in reward and addiction. 2015 , 16, 579-94	282
112	Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. 2016 , 7, 303	20
111	Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial. 2016 , 17, 372	4
110	Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. 2016 , 46, 27-45	25
109	Targeting the Endocannabinoid System in Psychiatric Illness. 2016 , 36, 691-703	21
108	Biomarkers for drug development in early psychosis: Current issues and promising directions. 2016 , 26, 923-37	32
107	Could cannabidiol be used as an alternative to antipsychotics?. 2016 , 80, 14-21	21
106	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [C]CURB. 2016 , 80, 691-701	37
105	Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. 2016 , 68, 34-9	31
104	The effects of Δtetrahydrocannabinol on the dopamine system. 2016 , 539, 369-377	176
103	Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. 2016 , 110, 49-58	12
102	Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. 2016 , 75, 14-21	14
101	Therapeutic Potential of Cannabinoids in Psychosis. 2016 , 79, 604-12	66
100	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. 2016 , 79, 997-1005	59

99	Social Stress and Psychosis Risk: Common Neurochemical Substrates?. 2016 , 41, 666-74	60
98	Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. 2016 , 266, 409-21	5
97	Lipids in psychiatric disorders and preventive medicine. 2017 , 76, 336-362	77
96	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. 2017 , 31, 757-769	14
95	Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments. 2017 , 75, 157-165	56
94	Interactions between cannabis and schizophrenia in humans and rodents. 2017 , 28, 811-823	6
93	Endocannabinoids and Lipid Mediators in Brain Functions. 2017 ,	
92	Investigating the link between drug-naive first episode psychoses (FEPs), weight gain abnormalities and brain structural damages: Relevance and implications for therapy. 2017 , 77, 9-22	17
91	Quantitative profiling of endocannabinoids and related -acylethanolamines in human CSF using nano LC-MS/MS. 2017 , 58, 615-624	21
90	A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. 2017 , 72, 310-324	91
89	Putative Role of Endocannabinoids in Schizophrenia. 2017 , 83-113	
88	The Endocannabinoid System and Human Brain Functions. 2017 , 115-186	3
87	Dual Disorders in Cannabis Misuse. 2017 , 61-69	
86	Stress Response in Cannabis Users and Psychosis. 2017 , 278-287	
85	Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. 2017 , 8, 399	19
84	Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders. 2018 , 309-339	1
83	Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project. 2018 , 50, 40-46	12
82	Study of sample preparation for determination of endocannabinoids and analogous compounds in human serum by LC-MS/MS in MRM mode. 2018 , 185, 602-610	20

81	Psychotomimetic and Cognitive Effects of Cannabis Use in the General Population. 2018 , 129-155	3
80	Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis. 2018 , 48, 2890-2902	8
79	Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. 2018 , 32, 825-849	23
78	Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?. 2018 , 43, 155-172	180
77	The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. 2018 , 44, 46-53	30
76	New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. 2018 , 5,	21
75	Prenatal immune activation potentiates endocannabinoid-related plasticity of inhibitory synapses in the hippocampus of adolescent rat offspring. 2018 , 28, 1405-1417	4
74	Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. 2018 , 18, e1700270	2
73	Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. 2018 , 32, 605-619	21
72	The endocannabinoid system in mental disorders: Evidence from human brain studies. 2018 , 157, 97-107	36
71	Psychosis and synthetic cannabinoids. 2018 , 268, 400-412	33
70	Dimensional Psychopathology. 2018 ,	4
69	The Apprehension/Fear and Somatic Preoccupation/Somatisation Dimensions. 2018 , 83-125	
68	Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. 2018 , 1044, 12-28	26
67	Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity. 2018 , 28, 841-849	30
66	Cannabidiol (CBD) use in psychiatric disorders: A systematic review. 2019 , 74, 282-298	59
65	Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders. 2019 , 81, 574-587	12
64	The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. 2019 , 8,	39

63	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. 2019 , 76, 1074-1084	32
62	Cannabidiol as a potential treatment for psychosis. 2019 , 9, 2045125319881916	45
61	Determination of anandamide in cerebrospinal fluid samples by disposable pipette extraction and ultra-high performance liquid chromatography tandem mass spectrometry. 2019 , 1130-1131, 121809	3
60	Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis. 2019 , 76, 914-923	46
59	Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans. 2019 , 9,	9
58	Role of the endocannabinoid system in neurological disorders. 2019 , 76, 95-102	10
57	The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. 2021 , 26, 4464-4474	7
56	A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. 2019 , 29, 330-348	20
55	Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients. 2019 , 52, 126-133	2
54	Familial abnormalities of endocannabinoid signaling in schizophrenia. 2019 , 20, 117-125	16
53	Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. 2020 , 50, 1862-1871	6
52	Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting. 2020 , 11, 628	5
51	Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias. 2020 , 127, 1359-1367	6
50	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. 2020 , 6, 21	10
49	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. 2020 , 88, 727-735	12
48	Differential effects of Δ^9 -tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model. 2020 , 15, e0230238	10
47	Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review. 2020 , 10,	24
46	Possible therapeutic applications of cannabis in the neuropsychopharmacology field. 2020 , 36, 217-234	16

45	Endocannabinoid System Components as Potential Biomarkers in Psychiatry. 2020 , 11, 315		39
44	Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis. 2020 , 10, 111		2
43	Fatty acid amide hydrolase is lower in young cannabis users. 2021 , 26, e12872		7
42	The Cannabinoid CB Receptor in Schizophrenia. 2021 , 6, 646-659		4
41	Endocannabinoid system in psychotic and mood disorders, a review of human studies. 2021 , 106, 110096		4
40	Systems biology approaches to study lipidomes in health and disease. 2021 , 1866, 158857		13
39	The Impact of Cannabidiol on Human Brain Function: A Systematic Review. 2020 , 11, 618184		3
38	Endocannabinoid-serotonin systems interaction in health and disease. 2021 , 259, 83-134		3
37	Efficacy of Cannabidiol for Δ^9 -Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review. 2021 , 10,		4
36	Cannabinoids, reward processing, and psychosis. 2021 , 1		4
35	Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?. 2021 , 22,		1
34	Exploring the relationship between recency and frequency of cannabis use and diminished expression and apathy as two dimensions of negative symptoms in first episode psychosis. A one-year follow-up study. <i>Schizophrenia Research</i> , 2021 , 236, 89-96	3.6	0
33	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. 2013 , 73-101		1
32	Have the genetics of cannabis involvement gone to pot?. 2014 , 61, 71-108		2
31	Cannabinoids and Endocannabinoids. 2016 , 1811-1841		2
30	Endocannabinoid Signaling in Reward and Addiction: From Homeostasis to Pathology. 2017 , 257-318		2
29	Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review. 2020 , 114, 158-171		7
28	Drugs of Abuse Induced-Subversion of the Peripheral Immune Response and Central Glial Activity: Focus on Novel Therapeutic Approaches. 2019 , 19, 281-291		5

27	Cannabinoids in health and disease. 2007 , 9, 413-30	131
26	Cannabinoids and their therapeutic applications in mental disorders?. 2020 , 22, 271-279	5
25	Schizophrenia. 2009 , 1, 387-96	
24	References. 2010 , 335-393	
23	Schizophrenia and Comorbid Substance Abuse [Pathophysiological and Therapeutic Approaches. 2011 , 321-363	
22	The Interface of Cannabis Misuse and Schizophrenia-Spectrum Disorders. 2011 , 289-320	1
21	Chronic Effects of Cannabinoid Drugs on Monoaminergic Systems and the Role of Endocannabinoids and Cannabinoid Receptors in Human Brain Disorders. 2013 , 213-238	
20	Investigating the Role of the Endocannabinoid System in Early Psychosis. 2017 , 2, 85-92	
19	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis.	1
18	Cannabis. 2019 , 183-188	
17	Endocannabinoid levels in patients with Parkinson disease with and without levodopa-induced dyskinesias.	
16	Medicinal Applications of Cannabidiol from the Genus Cannabis L.. 2020 , 201-241	
15	Endocannabinoids as potential biomarkers: It's all about pre-analytics.. 2021 , 22, 56-63	2
14	A biomarker-authenticated model of schizophrenia implicating NPTX2 loss of function. 2021 , 7, eabf6935	1
13	The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study.. 2022 , 10,	0
12	Cannabinoid-Based Medicine: Pharmacology and Drug Interactions. 2022 , 41-89	
11	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.. 2022 , 1-24	1
10	Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.. 2022 , 23,	0

- 9 Quantification of endocannabinoids in human cerebrospinal fluid using a novel micro-flow liquid chromatography-mass spectrometry method. **2022**, 1210, 339888 ○
- 8 Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and -Acylethanolamines by Liquid Chromatography-Tandem Mass Spectrometry.. **2022**, ○ 1
- 7 Cannabinoids and Endocannabinoids. **2022**, 1-29
- 6 Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients. **2022**, 27, ○
- 5 Cannabinoids and Endocannabinoids. **2022**, 2129-2157 ○
- 4 Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study. ○
- 3 Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. 026988112211486 ○
- 2 The Inflammatory Signals Associated with Psychosis: Impact of Comorbid Drug Abuse. **2023**, 11, 454 ○
- 1 Development and validation of a sensitive assay for the quantification of arachidonoylcyclopropylamide (ACPA) in cell culture by LCMS/MS. **2023**, 14, ○